Irit Ben-Chelouche

Director of Business Development, Harvard Medical School

Displaying: 31 - 36 of 36 Results

Novel methods for generating regulatory T-cells

Regulatory T-cells (Tregs) are key mediators of peripheral tolerance that can actively suppress effector T-cells, inhibit inflammation and mediate self-tolerance. Unlike naturally occurring Tregs (nTregs) which develop in the thymus,…


  • Arlene H. Sharpe
  • Loise Francisco
  • Vijay K. Kuchroo

A system for the continuous directed evolution of biomolecules

Researchers in the laboratory of Professor David Liu have developed a platform that enables the continuous directed evolution of gene-encoded molecules that can be linked to protein production in E. coli. During phage-assisted continuous evolution…


  • David R. Liu
  • Kevin M. Esvelt
  • Jacob Carlson
  • Ahmed Hussein Badran

Interaction-dependent PCR: Multiplexed identification of ligand-target pairs from DNA-encoded ligand/target libraries in a single solution-phase experiment

IDPCR is based on the melting temperature difference between duplex DNA formed intramolecularly versus intermolecularly. Binding of a target to its ligand would increase the effective molarity of single-stranded DNA oligonucleotides linked to the…


  • David R. Liu
  • David J. Gorin
  • Adam S. Kamlet
  • Lynn McGregor
  • Christoph E. Dumelin

Novel target in NK cell mediated antigen specific memory responses

The von Andrian laboratory discovered a novel mechanism for inducing antigen specific immunological memory. Their research examines the role of a molecular target not previously known to be associated with the natural killer (NK) cell mediated…


  • Ulrich H. von Andrian
  • Silke Paust

Small-molecule macrocycles: Potent and selective Src kinase inhibitors

Macrocyclic compounds have unique properties that allow them to cover regions of chemical space not addressed by other small-molecule structural classes. By performing an in vitro selection screen of a broad untargeted DNA-encoded library of 13,824…


  • David R. Liu
  • Ralph Elliot Kleiner

Bisphosphonates as novel adjuvants to enhance the adaptive immune response, validated with common types of vaccine antigens and commercial vaccines

Despite decades of adjuvant research, only a handful of adjuvants have been approved in seven major global markets and only two (Alum and GSK’s AS04) are licensed in the US. The availability of additional adjuvants has been minimized due to…


  • Ulrich H. von Andrian
  • Matteo Iannacone
  • Elena Tonti
  • Elliott Ashley Moseman

Page 4 of 4